泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301230 泓博医药

已收盘 12-22 15:00:00

{"stockData":{"symbol":"301230","market":"SZ","secType":"STK","nameCN":"泓博医药","latestPrice":30.41,"timestamp":1766387013000,"preClose":30.71,"halted":0,"volume":2341598,"delay":0,"changeRate":-0.0098,"floatShares":126000000,"shares":140000000,"eps":0.2622,"marketStatus":"已收盘","change":-0.3,"latestTime":"12-22 15:00:00","open":30.63,"high":30.98,"low":30.22,"amount":71416400,"amplitude":0.0247,"askPrice":30.41,"askSize":9,"bidPrice":30.4,"bidSize":5,"shortable":0,"etf":0,"ttmEps":0.2622,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766453400000},"marketStatusCode":5,"adr":0,"adjPreClose":30.71,"symbolType":"stock","openAndCloseTimeList":[[1766367000000,1766374200000],[1766379600000,1766386800000]],"highLimit":33.78,"lowLimit":27.64,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":139586605,"isCdr":false,"pbRate":4.18,"roa":"--","peRate":115.980168,"roe":"3.3%","epsLYR":0.12,"committee":0.42487,"marketValue":4245000000,"turnoverRate":0.0186,"status":1,"floatMarketCap":3820000000},"requestUrl":"/m/hq/s/301230/tweets","defaultTab":"tweets","newsList":[{"id":"2593544100","title":"泓博医药：未与阿里等开展C端健康医疗合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2593544100","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593544100?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:15","pubTimestamp":1766391313,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药12月22日在投资者关系平台上答复投资者关心的问题。依托支付宝体系的 10 亿级用户基础，“阿福”有望成为高频健康交互入口。基于此，我司目前未与阿里巴巴或其他互联网平台开展C端健康医疗类项目合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200015593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","ALBmain","301230","BK0216"],"gpt_icon":0},{"id":"2593107755","title":"泓博医药：公司需严格履行相关保密义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2593107755","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593107755?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:09","pubTimestamp":1766390950,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司跟礼来、诺和、辉瑞等这些公司或者他们旗下公司是否有相关合作？泓博医药回复：尊敬的投资者您好！公司服务的客户类型覆盖全球范围内的创新药企、制药企业、生物技术公司以及科研机构等。但根据合同约定及行业通行的商业保密要求，具体客户名称及合作细节不便对外披露，公司需严格履行相关保密义务，敬请理解。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200015016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2591116386","title":"泓博医药：截至2025年12月10日股东户数为14,645户","url":"https://stock-news.laohu8.com/highlight/detail?id=2591116386","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591116386?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:42","pubTimestamp":1765788133,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年12月10日股东人数是多少？泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2025年12月10日，公司的股东户数为14,645户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500018647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2590360301","title":"泓博医药：公司经营稳定业务持续向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2590360301","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590360301?lang=zh_cn&edition=full","pubTime":"2025-12-09 09:00","pubTimestamp":1765242059,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药12月08日在投资者关系平台上答复投资者关心的问题。股价走势受宏观环境、行业周期及市场情绪等多重因素影响，涨跌属于市场行为。公司目前经营稳定，业务发展持续向好，公司管理层对公司的未来发展充满信心，并将持续聚焦主营业务，不断提升公司经营质量和盈利能力，致力于为投资者创造长期、可持续的价值回报。未来如有相关计划，公司将及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900004758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2590360302","title":"泓博医药：帕拉米韦适用于流感病毒引起的感冒","url":"https://stock-news.laohu8.com/highlight/detail?id=2590360302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590360302?lang=zh_cn&edition=full","pubTime":"2025-12-09 09:00","pubTimestamp":1765242058,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问：近期看新闻，全国流感爆发，公司的产品是否涉及相关流感类；如果是，那么是否带起公司近期产品销量？麻烦尽可能详细分享一下泓博医药回复：尊敬的投资者您好！帕拉米韦是公司的商业化品种之一，适用于流感病毒引起的普通流行性感冒、甲型流行性感冒或乙型流行性感冒。关于产品的经营情况敬请关注公司的定期报告，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900004752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2581881523","title":"泓博医药（301230）披露2025年半年度权益分派实施公告，11月7日股价下跌2.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581881523","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581881523?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:40","pubTimestamp":1762526435,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，泓博医药报收于32.31元，较前一交易日下跌2.06%，最新总市值为45.1亿元。该股当日开盘32.76元，最高32.8元，最低32.24元，成交额达7035.15万元，换手率为1.73%。公司近日发布公告，披露2025年半年度权益分派实施方案。本次权益分派股权登记日为2025年11月13日，除权除息日为2025年11月14日。现金红利将由中国结算深圳分公司代派，部分股东由公司自行派发。本次权益分派实施后，除权除息参考价将相应调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700039443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2580237230","title":"泓博医药（301230）4875.55万股限售股将于11月3日解禁，占总股本34.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580237230","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580237230?lang=zh_cn&edition=full","pubTime":"2025-11-03 08:02","pubTimestamp":1762128159,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，泓博医药于11月3日将有4875.55万股限售股份解禁，为公司首发原股东限售股份，占公司总股本34.93%。本次解禁后，公司还有1397.08万股限售股份，占总股本10.01%。泓博医药主营业务：药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300001909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2579104507","title":"泓博医药（301230）2025年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579104507","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579104507?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:57","pubTimestamp":1761865028,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泓博医药发布2025年三季报。截至本报告期末，公司营业总收入5.14亿元，同比上升31.43%，归母净利润3474.96万元，同比上升127.96%。按单季度数据看，第三季度营业总收入1.62亿元，同比上升28.67%，第三季度归母净利润998.82万元，同比上升1462.85%。本报告期泓博医药盈利能力上升，毛利率同比增幅18.06%，净利率同比增幅73.45%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100010392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230"],"gpt_icon":0},{"id":"2579397395","title":"泓博医药(301230.SZ)发布前三季度业绩，归母净利润3474.96万元，增长127.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579397395","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579397395?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:51","pubTimestamp":1761731491,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泓博医药(301230.SZ)发布2025年三季度报告，该公司前三季度营业收入为5.14亿元，同比增长31.43%。归属于上市公司股东的净利润为3474.96万元，同比增长127.96%。归属于上市公司股东的扣除非经常性损益的净利润为2770.95万元，同比增长353.43%。基本每股收益为0.2489元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泓博医药(301230.SZ)发布前三季度业绩，归母净利润3474.96万元，增长127.96%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301230"],"gpt_icon":0},{"id":"2578204950","title":"泓博医药调整股权激励计划授予价格并完成预留授予","url":"https://stock-news.laohu8.com/highlight/detail?id=2578204950","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578204950?lang=zh_cn&edition=full","pubTime":"2025-10-28 21:36","pubTimestamp":1761658599,"startTime":"0","endTime":"0","summary":"中访网数据  上海泓博智源医药股份有限公司于2025年10月27日召开第四届董事会第四次会议，审议通过了调整2024年限制性股票激励计划授予价格及向激励对象授予预留限制性股票的议案。根据公司2024年年度权益分派方案实施情况，本次激励计划的授予价格由12.35元/股调整为12.02元/股。同时，公司向10名激励对象授予了23.00万股预留限制性股票，授予价格为12.02元/股。本次授予的激励对象为公司高级管理人员及核心技术(业务)骨干、外籍员工。公司表示，本次调整及授予事项符合相关法律法规及公司激励计划的规定，已取得必要的批准和授权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251028/31745329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2570105260","title":"股市必读：泓博医药（301230）9月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2570105260","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570105260?lang=zh_cn&edition=full","pubTime":"2025-09-26 01:00","pubTimestamp":1758819649,"startTime":"0","endTime":"0","summary":"截至2025年9月25日收盘，泓博医药报收于34.72元，下跌0.74%，换手率3.81%，成交量2.93万手，成交额1.03亿元。泓博医药是一家新药研发及商业化生产一站式综合服务商，公司业务涉及的治疗领域众多，其中包括减肥领域。当日关注点来自交易信息汇总：9月25日主力资金净流入469.77万元，显示主力对泓博医药的积极介入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600000466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2570030924","title":"泓博医药：公司业务涉及减肥领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2570030924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570030924?lang=zh_cn&edition=full","pubTime":"2025-09-25 09:06","pubTimestamp":1758762401,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)09月25日在投资者关系平台上答复投资者关心的问题。投资者提问：您好 贵公司在减肥药创新领域有无具体关键技术 如果有 在业务拓展方面进展如何 谢谢泓博医药回复：尊敬的投资者您好！泓博医药是一家新药研发及商业化生产一站式综合服务商，公司业务涉及的治疗领域众多，其中包括减肥领域。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092500004756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2566922457","title":"9月12日泓博医药现1179.2万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2566922457","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566922457?lang=zh_cn&edition=full","pubTime":"2025-09-12 17:03","pubTimestamp":1757667828,"startTime":"0","endTime":"0","summary":"证券之星消息，9月12日泓博医药发生大宗交易，交易数据如下：近三个月该股共发生8笔大宗交易，合计成交9800.0手，折价成交8笔。该股近期无解禁股上市。截至2025年9月12日收盘，泓博医药(301230)报收于37.75元，上涨2.28%，换手率5.38%，成交量4.14万手，成交额1.54亿元。该股近半年内有股东持股变动，合计净减持137.0万股，股东增减持明细如下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091200026327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2566943249","title":"泓博医药：公司不涉及相关技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2566943249","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566943249?lang=zh_cn&edition=full","pubTime":"2025-09-12 08:52","pubTimestamp":1757638330,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)09月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司是否参与脑机接口相关技术领域进行技术储备和研发？泓博医药回复：尊敬的投资者您好！公司不涉及相关技术。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091200005783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2566986085","title":"股市必读：泓博医药（301230）9月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2566986085","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566986085?lang=zh_cn&edition=full","pubTime":"2025-09-11 01:52","pubTimestamp":1757526736,"startTime":"0","endTime":"0","summary":"截至2025年9月10日收盘，泓博医药报收于36.51元，下跌0.52%，换手率6.4%，成交量4.92万手，成交额1.81亿元。董秘最新回复投资者： 大股东11月1日解禁，请问大股东是否会在解禁后减持？截至目前，公司未收到相关股东的减持计划或通知，若未来涉及相关安排，将严格按照法律法规及监管要求，及时履行信息披露义务。当日关注点来自交易信息汇总：9月10日主力资金净流出1253.46万元，散户资金净流入2641.09万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100001627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"gpt_icon":0},{"id":"2566609125","title":"泓博医药：公司自2019年起布局CADD/AIDD技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2566609125","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566609125?lang=zh_cn&edition=full","pubTime":"2025-09-10 20:48","pubTimestamp":1757508508,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药09月09日在投资者关系平台上答复投资者关心的问题。贵公司作为上海本地AI+制药企业，是否重大利好积极促进贵公司业务发展？公司自2019年起布局CADD/AIDD技术，项目应用涵盖药物分子设计、活性预测、分子筛选等环节。未来，公司将继续推进内部平台的模块化建设与算法优化，以推动AI在医药研发领域的深度赋能。另外，AI技术尚处于持续演进阶段，也敬请广大投资者理性看待技术发展进程，注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091000035746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2566865059","title":"泓博医药：公司订单模式主要分为FTE模式和FFS模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2566865059","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566865059?lang=zh_cn&edition=full","pubTime":"2025-09-09 11:36","pubTimestamp":1757389001,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药09月08日在投资者关系平台上答复投资者关心的问题。具体合作方信息因商业保密条款限制不便透露。公司的订单模式主要分为两种，FTE模式和FFS模式，FTE模式是按工时计费，根据与客户约定的研发人员数量、工时和合同约定费率进行收费，按月确认收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090900015459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2566505906","title":"泓博医药：研发平台建设以构建核心技术壁垒为战略核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2566505906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566505906?lang=zh_cn&edition=full","pubTime":"2025-09-09 11:36","pubTimestamp":1757389001,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)09月08日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好，欣闻贵公司研发平台项目逐步上量，请问贵公司研发平台需要多少在研项目可以真正有效提振公司业绩？泓博医药回复：尊敬的投资者您好！公司研发平台的建设始终以构建和巩固核心技术壁垒为战略核心，而非单纯追求在研项目的数量。我们深信，通过对前沿技术的持续投入与深度挖掘，可以为公司带来长期、可持续的竞争力与价值提升。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090900015457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"gpt_icon":0},{"id":"2563706798","title":"泓博医药（301230）2025年中报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2563706798","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563706798?lang=zh_cn&edition=full","pubTime":"2025-08-29 06:44","pubTimestamp":1756421093,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泓博医药发布2025年中报。截至本报告期末，公司营业总收入3.53亿元，同比上升32.73%，归母净利润2476.14万元，同比上升54.99%。按单季度数据看，第二季度营业总收入1.83亿元，同比上升35.75%，第二季度归母净利润1278.76万元，同比上升3.89%。本报告期泓博医药盈利能力上升，毛利率同比增幅17.46%，净利率同比增幅16.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900007370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230"],"gpt_icon":0},{"id":"2562742967","title":"泓博医药：上半年净利2476.14万元，同比增54.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562742967","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562742967?lang=zh_cn&edition=full","pubTime":"2025-08-27 21:45","pubTimestamp":1756302326,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0216","301230"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766405094365,"stockEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":-0.0032},{"period":"3month","weight":-0.1355},{"period":"6month","weight":0.0153},{"period":"1year","weight":0.141},{"period":"ytd","weight":0.2175}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":-0.0143},{"period":"3month","weight":0.0184},{"period":"6month","weight":0.1579},{"period":"1year","weight":0.1544},{"period":"ytd","weight":0.1607}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海泓博智源医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"14645人(较上一季度减少0.02%)","perCapita":"8577股","listingDate":"2022-11-01","address":"上海市浦东新区庆达路315号23幢","registeredCapital":"13958万元","survey":"　　上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是替格瑞洛API及关键中间体、帕拉米韦中间体、左卡尼汀、奥拉西坦、本维莫德。","listedPrice":40},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泓博医药,301230,泓博医药股票,泓博医药股票老虎,泓博医药股票老虎国际,泓博医药行情,泓博医药股票行情,泓博医药股价,泓博医药股市,泓博医药股票价格,泓博医药股票交易,泓博医药股票购买,泓博医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}